Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review

BACKGROUND: Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors reduce atherosclerotic cardiovascular disease (ASCVD) events in patients with prior ASCVD and type 2 diabetes; however, this benefit is uncertain in patients without established ASCVD. METHODS AND RESULTS: Large‐scale cardiovascular outco...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahman, Hammad, Khan, Safi U., Lone, Ahmad N., Ghosh, Priyanka, Kunduru, Mahathi, Sharma, Saurabh, Sattur, Sudhakar, Kaluski, Edo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492958/
https://www.ncbi.nlm.nih.gov/pubmed/37581396
http://dx.doi.org/10.1161/JAHA.123.030578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492958/
https://www.ncbi.nlm.nih.gov/pubmed/37581396
http://dx.doi.org/10.1161/JAHA.123.030578

Ejemplares similares